Actively Recruiting
An Imaging Study of Polyvascular Disease
Led by Harbin Medical University · Updated on 2024-12-27
1100
Participants Needed
1
Research Sites
115 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
1. Establish a multimodality imaging database for PVD, improve the one-stop screening process for early PVD based on artificial intelligence, build a full-cycle control information platform, and promote the construction and standardization of a multidisciplinary co-morbidity and co-management diagnosis and treatment model. 2. Based on non-invasive, zero-contrast ocular OCTA combined with one-stop CTA imaging of the heart and brain, construct an integrated "eye-heart-brain" early warning model for PVD, and explore a potential non-invasive and convenient early warning system for PVD. 3. Based on the multi-omics, investigate EVs-mediated intercellular communication network, elucidate the roles and regulatory mechanisms of EVs in the development of PVD, search for potential targets for intervention, and construct an artificial intelligence-based "pan-vascular score" risk assessment system based on the combination of multi-modality imaging and multi-omics biomarkers.
CONDITIONS
Official Title
An Imaging Study of Polyvascular Disease
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients with coronary artery disease showing 50% or more narrowing in any coronary artery on angiography
- Age 18 years or older
- Proposed use of OCT-IVUS integrated imaging system (for Task 1)
- Patients with coronary artery disease or with stroke or TIA confirmed by a neurologist (for Task 2)
- Able to provide written informed consent before any study procedures
You will not qualify if you...
- Severely tortuous or calcified coronary arteries making OCT-IVUS imaging difficult (Task 1)
- Uncontrolled congestive heart failure or acute left heart failure
- Claustrophobia
- Left main stem artery occlusion
- Planned coronary artery bypass grafting (CABG)
- Uncontrolled severe ventricular arrhythmia
- Active bleeding or severe bleeding tendency
- Acute stroke
- Hemodynamic instability or unstable cardiac electrical activity including shock
- Severe renal insufficiency or anuria unless dialysis is planned
- Contraindications to contrast media use
- Severe psychiatric or systemic illness causing poor cooperation
- Patients judged unsuitable for study participation by the investigator
- Inability to comply with follow-up schedule (Task 2)
- Life expectancy less than 6 months (Task 2)
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
The Second Affiliated Hospital of Harbin Medical University
Harbin, Heilongjiang, China, 150000
Actively Recruiting
Research Team
M
Minghao Liu, MD.
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here